ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)

Wired purchased four injectable peptide vials for $376.20 from a Brooklyn bodega and sent them to Finnrick, an Austin-based testing startup. Lab results in August showed the vials contained no active ingredients like BPC-157 or retatrutide. The samples were either mislabeled or degraded, though they had low levels of heavy metals. The findings highlight risks in the unregulated peptide market.
Tap to vote and see what everyone thinks.
Summary by ByteBrief